The global “acute bacterial skin”and skin structure infections treatment market will derive growth from the increasing usage approvals in recent years. According to a report published by Fortune Business Insights, titled “Acute Bacterial Skin and Skin Structure Infections Treatment: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 7,270.9 Mn in 2018. Fortune Business Insights has predicted that the market will reach US$ 14,972.6 Mn by the end of 2026, thereby exhibiting a CAGR of 9.5%.
Recent developments in acute bacterial skin and skin structure infections treatment methods such as the advent of novel drugs and therapies will favor growth of the global market. The report stresses on the latest industry development and signifies the impact of these developments on the acute bacterial skin and skin structure infections treatment market value. The report includes segmentation of the market based on several factors such as infection type, route of administration,distribution channel, and regional demographics. Besides these, the report provides insights into a few of the factors that have constituted for the increase in the global acute bacterial skin and skin structure infections treatment market value.
The increasing prevalence of acute bacterial skin and skin structure infections around the world has led to increasing demand for acute bacterial skin and skin structure infections treatment options across the world. On account of the aforementioned factors, companies are looking to generate acute bacterial skin and skin structure infections treatment market revenue.
Omadacycline’s FDA Approval to Benefit Market Growth
The increasing demand for acute bacterial skin and skin structure infections treatment options is encouraging healthcare manufacturers to come up with newer therapies and recombinant drugs. In the wake of such high demand, regulatory authorities have eased off their reluctance on approving drugs with minimal side effects. Increasing regulatory approvals will have a positive impact on the global acute bacterial skin and skin structure infections treatment market. In 2018, the Food and Drug Administration passed approval for the usage of omadacycline in the treatment of patients diagnosed with acute bacterial skin and skin structure infections (ABSSSI). The ability of omadacycline to act in various drug delivery methods such as oral and intravenous form will lead to a rising uptake among end users globally. Fortune Business Insights has predicted that the approval for omadacycline will have a positive impact on the global acute bacterial skin and skin structure infections treatment market in the forthcoming years.
An Overview of the Impact of COVID-19 on this Market:
The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.
We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.
Merck & Co., Inc andPfizer Inc. Contribute Significantly Towardsacute bacterial skin and skin structure infections Treatment Market Revenue
Increasing mergers and acquisitions (M&As) are favoring growth of the market in recent years. The report provides a detailed analysis of key mergers and acquisitions in the market and signifies their impact on the global market. Merck & Co., one of the leading companies, has till date, completed acquisition of several companies that are engaged in the research and development of drugs and therapies for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Pfizer Inc., is another company that has adopted exceptional business strategies that have directly made a significant impact on the growth of the global acute bacterial skin and skin structure infections treatment market. Fortune Business Insights has predicted together, Merck & Co. and Pfizer will account for the maximum market share during the forecast period.
Fortune Business Insights has profiled some of the leading acute bacterial skin and skin structure infections treatment market companies and signified their impact on the global market. A few of the leading companies that have made significant growth contributions are Merck & Co., Inc., Pfizer Inc., MELINTA THERAPEUTICS, INC., ALLERGAN, Paratek Pharmaceuticals, Inc., Cumberland Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd.
Related Reports :
- Continuous Renal Replacement Therapy Market
- Dental Prosthetics Market
- Global Acute Bacterial Skin and Skin Structure Infections Treatment Market
- Global Digital Blood Pressure Monitor Market
- Insulin Pumps Market
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune – 411045, Maharashtra, India.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245